A route to new cancer therapies: the FA pathway is essential in BRCA1- or BRCA2-deficient cells

Christophe Lachaud; John Rouse

doi:10.1038/nsmb.3276

A route to new cancer therapies: the FA pathway is essential in BRCA1- or BRCA2-deficient cells

Christophe Lachaud, John Rouse (Lead / Corresponding author)

MRC PPU

Research output: Contribution to journal › Article

2 Citations (Scopus)

332 Downloads (Pure)

Abstract

Mutations in the BRCA1 and BRCA2 genes strongly predispose carriers to breast and ovarian cancers. Two new studies reveal that FANCD2, a key component of the Fanconi anemia pathway, is essential for the survival of cells with BRCA1 or BRCA2 mutations. These findings pave the way for new 'synthetic lethal' strategies to kill BRCA-mutated cancers.

Original language	English
Pages (from-to)	701-703
Number of pages	3
Journal	Nature Structural & Molecular Biology
Volume	23
Issue number	8
DOIs	https://doi.org/10.1038/nsmb.3276
Publication status	Published - 3 Aug 2016

Keywords

Cancer
DNA damage and repair
Tumour-suppressor proteinis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/nsmb.3276

Author Accepted ManuscriptAccepted author manuscript, 184 KB

Cite this

@article{51660d4ce5b545158ff0b6ba83a7f790,

title = "A route to new cancer therapies: the FA pathway is essential in BRCA1- or BRCA2-deficient cells",

abstract = "Mutations in the BRCA1 and BRCA2 genes strongly predispose carriers to breast and ovarian cancers. Two new studies reveal that FANCD2, a key component of the Fanconi anemia pathway, is essential for the survival of cells with BRCA1 or BRCA2 mutations. These findings pave the way for new 'synthetic lethal' strategies to kill BRCA-mutated cancers.",

keywords = "Cancer, DNA damage and repair, Tumour-suppressor proteinis",

author = "Christophe Lachaud and John Rouse",

year = "2016",

month = aug,

day = "3",

doi = "10.1038/nsmb.3276",

language = "English",

volume = "23",

pages = "701--703",

journal = "Nature Structural & Molecular Biology",

issn = "1545-9993",

publisher = "Nature Publishing Group",

number = "8",

}

TY - JOUR

T1 - A route to new cancer therapies

T2 - the FA pathway is essential in BRCA1- or BRCA2-deficient cells

AU - Lachaud, Christophe

AU - Rouse, John

PY - 2016/8/3

Y1 - 2016/8/3

N2 - Mutations in the BRCA1 and BRCA2 genes strongly predispose carriers to breast and ovarian cancers. Two new studies reveal that FANCD2, a key component of the Fanconi anemia pathway, is essential for the survival of cells with BRCA1 or BRCA2 mutations. These findings pave the way for new 'synthetic lethal' strategies to kill BRCA-mutated cancers.

AB - Mutations in the BRCA1 and BRCA2 genes strongly predispose carriers to breast and ovarian cancers. Two new studies reveal that FANCD2, a key component of the Fanconi anemia pathway, is essential for the survival of cells with BRCA1 or BRCA2 mutations. These findings pave the way for new 'synthetic lethal' strategies to kill BRCA-mutated cancers.

KW - Cancer

KW - DNA damage and repair

KW - Tumour-suppressor proteinis

U2 - 10.1038/nsmb.3276

DO - 10.1038/nsmb.3276

M3 - Article

C2 - 27487393

SN - 1545-9993

VL - 23

SP - 701

EP - 703

JO - Nature Structural & Molecular Biology

JF - Nature Structural & Molecular Biology

IS - 8

ER -

A route to new cancer therapies: the FA pathway is essential in BRCA1- or BRCA2-deficient cells

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this